Evelyn Wong· @EvelynWongYT · X·· 15 小时前评分70
正文 · 机器翻译
QTX3034 + cetuximab ± mFOLFOX6 治疗 KRAS G12D mCRC：初步结果
👉 ORR：25% vs 50%
👉 DCR：75% vs 90%
为加用化疗带来积极信号。队列规模较小；仍需持久性 & 比较数据！
#ESMO26 #ESMOAmbassadors @OncoAlert
41 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
788RO按 Rapid oral: Gastrointestinal tumours, lower digestive 对上
Encorafenib plus cetuximab (EC) beyond progression in combination with FOLFIRI in BRAF V600E metastatic colorectal cancer (mCRC) patients (pts) progressing on EC: Results from the ECLYPse phase II trial
https://esmocongress.esmo.orgNCT06578559NCT06578559按 - **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC 对上
- **标题 / Title：** Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
https://esmocongress.esmo.orgNCT06640166NCT06640166按 - **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. 对上
- **标题 / Title：** Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
https://esmocongress.esmo.org来源：Evelyn Wong · x.com